Neurocrine Biosciences Set to Share Q2 2025 Financial Insights

Author: Evelyn Baker Updated: 07-09-2025 04:12 PM

Neurocrine Biosciences Announces Upcoming Financial Conference Call

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leader in the field of neuroscience, is excited to inform stakeholders about its scheduled conference call and webcast. The event is set for the afternoon of July 30, where financial results for the second quarter of 2025 will be shared. This moment allows the organization to review its achievements and future direction.

Details of the Conference Call and Webcast

On July 30, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), Neurocrine will host its conference call. A press release summarizing the second-quarter results will be made available at 1:00 p.m. PT (4:00 p.m. ET) on the same day. The call will offer insights into the company’s quarterly performance and ongoing projects.

Participants can access the call through a simple dial-in process:

Domestic Call Number: 800-225-9448
International Call Number: 203-518-9708
Conference ID: NBIX

Additionally, those interested in the webcast can find it on the Neurocrine Biosciences website within the Investors section. This will provide an opportunity for stakeholders to engage with the information in real-time and revisit the discussion later, as it will be available for replay approximately one hour post-event.

About Neurocrine Biosciences

Neurocrine Biosciences stands at the forefront of neuroscience-focused biopharmaceuticals with a commitment to serving people who need innovative solutions for under-addressed conditions. Their mission is to relieve suffering through the development of transformative therapies aimed at neurological, neuroendocrine, and neuropsychiatric disorders.

With a robust portfolio, Neurocrine boasts several FDA-approved therapies targeting various conditions, including treatments for tardive dyskinesia and chorea linked to Huntington's disease, among others. Moreover, their extensive pipeline is poised to deliver additional therapies, with numerous candidates currently in mid- to late-stage clinical development. This ongoing commitment underlines their belief in the power of brave science to enable positive health outcomes.

Innovative Solutions for Complex Conditions

During the upcoming conference call, stakeholders can also look forward to hearing about advancements in Neurocrine's therapeutic areas. Their focus remains on leveraging unique insights into neuroscience to develop patient-centric solutions. Highlights from the recent clinical trials and developmental milestones will likely be discussed, enlightening investors about the company's trajectory and goals.

Follow Neurocrine Biosciences

For those wishing to engage actively with Neurocrine Biosciences' journey, the company encourages following their updates across social media platforms, including LinkedIn, X, and Facebook. These channels are great resources for the latest news, research findings, and insights into their ongoing missions.

Frequently Asked Questions

What will Neurocrine discuss during the conference call?

Neurocrine will cover its second quarter financial results and provide updates on ongoing projects and therapies in development.

When is the financial conference call scheduled?

The call is slated for July 30, 2025, at 1:30 p.m. Pacific Time.

How can I access the conference call?

Participants can dial in using the provided domestic or international number to join the call.

Where can I find more information about Neurocrine?

More information is available on Neurocrine Biosciences' official website under the Investors section.

What therapies does Neurocrine Biosciences focus on?

The company focuses on treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio and pipeline.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.